RE: SRA73717 May 2024 10:57
Hi Potnak - whilst your 'repackaged for selling on' theory is reasonable, surely Sar/CPF would have been able to put together all the data required to maximise its appeal for onward development? Sierra had already completed PI/II trials so wouldn't that mean 737 is effectively P3-ready in respect to combo trials with Gemcitabine and/or Cisplatin? Hmmmm, all just mysteries of the bleedin' universe.
Some info for anyone new here wondering what's going on with 737 -
"Under the terms of the Licensing Agreement, an immediate upfront payment of US$0.5 million is due to CPF. An additional fee made up of up to US$1.0 million cash and 500,000 shares in the Licensee Company (the "Consideration Shares") may be payable upon the sooner of 12 months following the signing of the Licensing Agreement, or the event of the Licensee Company achieving certain commercial and material financing objectives. A further announcement regarding any future income, including any Consideration Shares which may be issued, will be made at the appropriate time.
Additional payments to the aggregate amount of up to US$289 million may become payable to CPF under the Licensing Agreement, subject to achievement of certain development, regulatory and commercial milestones which may or may not be achieved. The Licensee Company will also pay tiered high single digit royalties to CPF on the net sales of any product successfully developed and commercialised.
Under the terms of Sareum's co-development agreements with CPF and Cancer Research Technology Ltd, Sareum is entitled to receive 27.5% of any income arising from this licensing of the SRA737 programme. Therefore, Sareum is entitled to receive US$137,500 from the upfront fee payable under the Licensing Agreement, as well as 27.5% of any future payments payable by the Licensee Company (including any Consideration Shares received), under the terms of the Licensing Agreement."
Sign In
Follow the stocks
